focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
PYC: Shares in Issue only 97m
Market Capitalisation only £8m
I can see day trading brigades are marching...
Synairgen is a one-pony play, an old technology/product, many years clinical trials mainly for COPD patients exacerbation caused by infection; Market Capitalisation £344m which is 22 times of Evgen's £15m Market Capitalisation. Puzzling to see so many small holders rush to sell their holdings of Evgen.
The Global Non Receptor Tyrosine Protein Kinase TYK2 Market research report covers the profiles of major players in the market:
Array BioPharma Inc
Bristol-Myers Squibb Company
Nimbus Therapeutics LLC
Pfizer Inc
Portola Pharmaceuticals Inc
Sareum Holdings Plc
Takeda Pharmaceutical Company Ltd
Theravance Biopharma Inc
last year signed Licence agreement with Juvenescence for non-pharmaceutical applications(non-core value asset) with $10.5m milestones only, plus royalties on sales revenue if Juvenescence can speedily develop and launch these type of products to the market.
Very disappointing news and saddened to see the 30% SP drop. I just checked last June AUDITED FINANCIAL HIGHLIGHTS and make interesting reading: Loss of June 2019 - June 2020 is £0.99m, this means the monthly cash burning is 90k, the previous year 2019: loss of £1.45m which is monthly cash burning around 120k. Cash at bank as of 30 June 2020 was £1.80m
plus the expected Tax Credit will be received usually this month, if estimated monthly cash burning of 100k from July 2020 to Jan 2021, 7 months = 700k, so it should be not difficult to work out how much cash in bank left, my guess is between £1.1-1,3m. See the last AUDITED FINANCIAL HIGHLIGHTS, make your own calculation and judgement.
· As previously indicated, R&D Tax Credit of £0.23m was received in January 2020.
· Raised £1.02m (gross) in June 2020 through a placing by Hybridan LLP in conjunction with an offer via PrimaryBid to progress the Company's TYK2/JAK1 drug development programmes as well as for working capital purposes.
· Loss on ordinary activities for the year ended 30 June 2020 (after taxation) of £0.99m (2019: loss of £1.45m), reflecting the Company's careful management of cash resources.
· Cash at bank as of 30 June 2020 was £1.80m (£1.0m as of 31 December 2019; £0.92m as of 30 June 2019).
· As announced on 17 December 2019, the Company confirmed that all directors had entered a voluntary salary deferral scheme, whereby 33% of directors' salaries were being deferred until further notice.
disappointing that sold volume is 5 times more than bought, thought that the CEO interview was very positive one.
'Nature' article identifies TYK2 as key causative genetic mechanism for coronavirus, is it possible to combine Sareum TYK2/JAK1 inhibitor SDC-1801 with Synairgen therapeutics to have better ****tail effect for treatment of severe symptom of covid-19. https://www.proactiveinvestors.co.uk/companies/news/936394/sareum-up-as--nature--article-identifies-tyk2-as-key-causative-genetic-mechanism-for-coronavirus-936394.html
Scientists have identified a new variant of coronavirus which may be linked to the faster spread of COVID-19 in the South of England. https://www.sciencefocus.com/news/covid-19-what-is-the-new-variant-of-coronavirus/
Anyone know the time/date of Evgen's last placing, thanks.
I fully agree with the view that widely expanding the number of cancers they are targeting which are some of the most common cancers, prostate, lung, ovarian, bowel and others with huge market potential for the combination treatment only don't even consider the stand alone treatment with chk1. Even just one of the cancer combination treatment successful, the revenues will be substantial, so the success rate is pretty high enough to hold.
�600K per year for such achievement? too little, should be million!
Very disappointed with the latest development as so much resources put into the USA cough cold market and now washing hands to say the expensively assembled sales force and costly acquired cough cold products are not working in one of the worst cough cold season in N. America, even reported that a Chinese herbal syrup distributor made fortune for quickly selling off CHM cough syrup for �50 per bottle. Sadly this will quickly head towards the penny stock range if workable measures not taking quickly.
For cough cold products to venture into US market must have very deep pocket to sustain the amount of cash burn.
I just want to know whether Angle's so called liquid biopsy in other words collecting cancer cells from blood, if it is, anyone can compare and tell the £40m MCAP of Angle to the much less MCAP of some the AIM oncology drug development stage companies such as Sar and Val which got 2 late clinical stage oncology drugs and a mere MCAP of £4m.
comparing minnow Sar rising 22%, the share price of VER is still falling, anyone reckon this will touch the 20s range back in 2104? What's the real reason of the falling share price, is it the huge sales cost and the very moderate revenue income reported in the half yearly results?